CompletedNCT05064319
Gabapentin study for people with bipolarity who use cannabis
About this title
Read the official source — NCT05064319Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CharlestonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: February 24, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Medical University of South Carolina
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05064319
- Official title
Show the full official title
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Charleston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medical University of South Carolina, a university.
Did this study involve medication?
Yes. The study involved medication, including Gabapentin and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
